Canagliflozin Hemihydrate: SGLT2 Inhibitor for Diabetes & Glucose Metabolism Research

Executive Summary: Canagliflozin hemihydrate (APExBIO C6434) is a well-characterized small molecule SGLT2 inhibitor, widely leveraged in diabetes mellitus and glucose metabolism research (APExBIO product page). Its mechanism is highly specific for sodium-glucose co-transporter 2 (SGLT2), with no observed inhibition of mTOR signaling in sensitive yeast models (Breen et al., 2025). The compound demonstrates high solubility in DMSO (≥83.4 mg/mL) and ethanol (≥40.2 mg/mL), but is insoluble in water, requiring organic solvents for experimental use. It is provided at ≥98% purity, confirmed by HPLC and NMR, and is intended strictly for research purposes, not for diagnostic or therapeutic use. These properties, along with its pathway specificity, make Canagliflozin hemihydrate a benchmark SGLT2 inhibitor in metabolic disorder studies (contrast: DDP-4.com protocol guide).

Biological Rationale

Canagliflozin hemihydrate, also known as JNJ 28431754 hemihydrate, is classified as a small molecule SGLT2 inhibitor. SGLT2 is a renal transporter responsible for reabsorbing filtered glucose in the proximal tubule of the kidney (APExBIO). Inhibition of this transporter reduces blood glucose by promoting glucosuria. This mechanism is central to glucose homeostasis and is widely used in preclinical models of diabetes mellitus and metabolic syndrome (see: Translational Diabetes Research perspective). The compound’s specificity for SGLT2 allows for precise interrogation of renal glucose reabsorption pathways without off-target effects typical of broader-acting metabolic agents.

Mechanism of Action of Canagliflozin (hemihydrate)

Canagliflozin hemihydrate acts by selectively inhibiting SGLT2 in the renal proximal tubule. This action decreases renal glucose reabsorption, increasing urinary glucose excretion and lowering systemic glucose levels. The chemical structure, C₂₄H₂₆FO_5.5S (molecular weight: 453.52), provides high selectivity for SGLT2 over SGLT1 and other transporters. The compound is ineffective against unrelated pathways such as mTOR/TOR signaling, as confirmed by negative results in drug-sensitized yeast growth assays (Breen et al., 2025). This distinguishes Canagliflozin hemihydrate from polypharmacological agents, facilitating clean mechanistic studies of the glucose homeostasis pathway.

Evidence & Benchmarks

• Canagliflozin hemihydrate inhibits SGLT2-mediated glucose reabsorption, driving glucosuria in renal models (APExBIO).
• It is insoluble in water but shows high solubility in DMSO (≥83.4 mg/mL) and ethanol (≥40.2 mg/mL) at room temperature (25°C) (APExBIO).
• Purity exceeds 98% by HPLC and NMR validation, ensuring batch-to-batch reproducibility for research applications (APExBIO).
• No TOR/mTOR inhibition observed in drug-sensitized yeast at standard screening concentrations (Breen et al., 2025, DOI).
• Shipped on blue ice and stored at -20°C to preserve stability and purity; long-term storage of solutions is not recommended (APExBIO).
• Benchmark studies emphasize pathway specificity, distinguishing Canagliflozin hemihydrate from compounds with mTOR or off-target metabolic effects (see: Mechanistic Insights).

Applications, Limits & Misconceptions

Canagliflozin hemihydrate is used as a reference SGLT2 inhibitor in models of diabetes, metabolic syndrome, and glucose homeostasis. Its specificity allows for direct assessment of renal glucose reabsorption inhibition without mTOR pathway interference (Breen et al., 2025). The compound is not valid for diagnostic or clinical applications, nor as a tool for mTOR inhibition or immunomodulation. It is an optimal reagent for mechanistic studies, phenotypic screens, and metabolic pathway validation.

Common Pitfalls or Misconceptions

• Not an mTOR inhibitor: Canagliflozin hemihydrate does not inhibit mTOR/TOR signaling at relevant concentrations in yeast or mammalian models (Breen et al., 2025).
• Not soluble in water: The compound must be dissolved in DMSO or ethanol for experimental use; water-based formulations are ineffective (APExBIO).
• For research use only: It is not approved for diagnostic, therapeutic, or clinical use.
• Solution stability: Prepared solutions are not suitable for long-term storage; use promptly after dissolution (APExBIO).
• Not a pan-metabolic inhibitor: Its activity is limited to SGLT2; it does not affect SGLT1, mTOR, or unrelated metabolic targets.

Workflow Integration & Parameters

Canagliflozin hemihydrate is typically supplied as a solid powder, with recommended storage at -20°C. For use, dissolve in DMSO or ethanol to achieve target concentrations (common stock: 10–50 mM in DMSO). For in vitro assays, dilute as appropriate in buffer or media, ensuring final DMSO concentration does not exceed 0.1–1% (v/v). APExBIO supplies the C6434 kit with validated QC metrics, streamlining integration into metabolic, glucose uptake, and renal transport assays (APExBIO).

For detailed stepwise protocols and troubleshooting, see the Applied SGLT2 Inhibitor for Glucose Metabolism guide, which this article extends by providing updated evidence for mTOR pathway exclusion and advanced stability handling recommendations.

Conclusion & Outlook

Canagliflozin hemihydrate remains a gold-standard tool for SGLT2 inhibition in translational diabetes and metabolic disorder research. Its specificity for SGLT2, high purity, and well-validated lack of mTOR inhibition enable precise pathway interrogation. Researchers seeking to dissect renal glucose reabsorption or benchmark SGLT2 activity can rely on the robust, stable supply from APExBIO (Canagliflozin (hemihydrate)). This article clarifies the molecular and experimental boundaries, updating prior reviews (contrast: Translational Diabetes Research) by integrating recent yeast model evidence for pathway specificity. As metabolic research advances, pathway-pure inhibitors like Canagliflozin hemihydrate will remain essential for dissecting glucose homeostasis without off-target complications.